Optimizing Biochemical Assays for Kinase Activity in Drug Discovery

The precise measurement of kinase activity remains one of the cornerstones of targeted drug discovery. Kinases regulate key intracellular pathways, and their dysregulation is linked to numerous diseases, including cancer, metabolic conditions, and neurodegenerative disorders. To design effective inhibitors or modulators, it’s essential to rely on biochemical assays that provide accurate, reproducible, and sensitive detection of kinase function. These tools are constantly evolving, incorporating innovative technologies such as fluorescent ligands and novel detection formats that optimize performance across high-throughput settings. 

Kinase Activity in Drug Discovery: Mechanisms and Applications

Kinases are enzymes that catalyze the transfer of phosphate groups from adenosine triphosphate (ATP) to specific substrates. This process, known as phosphorylation, is crucial for regulating cellular functions, including cell signaling, growth, and metabolism.  Understanding kinase activity is essential for identifying therapeutic candidates and developing robust biochemical assays for drug screening.

Kinases possess a conserved catalytic domain that makes them amenable to drug targeting, particularly with small-molecule inhibitors that bind covalently or non-covalently to the kinase active site or allosteric sites, preventing phosphorylation and halting downstream signaling pathways, which ultimately inhibits cell proliferation.

Since the approval of the first kinase inhibitor, imatinib, kinase-targeted therapies have transformed the landscape of cancer treatment. However, applications of biochemical kinase assay systems go beyond oncology, extending to cardiovascular, autoimmune, and neurological research. 

Figure 1. The four types of allosteric kinase inhibitors. Allosteric inhibitors that bind to allosteric pockets adjacent to the ATP pocket, but do not overlap with the ATP-binding pocket, are defined as type III inhibitors. When the binding pockets are distant from the ATP-binding pocket, they are defined as type IV inhibitors. Small molecules that bind the pseudokinase domain (JH2) are defined as type VI inhibitors while those that bind the extracellular domain (ECD) are defined as type VII. Source: Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther. 2021 Dec 20;6(1):423.

Advanced Biochemical Assay Formats for Kinase Detection

Modern kinase drug discovery relies on biochemical assays that balance sensitivity, throughput, and safety. While traditional radiometric assays remain the gold standard for reliability, advanced non-radioactive formats now dominate due to scalability and safety. They are generally classified into two main categories:

1. Activity assays directly measure the catalytic function of kinases, typically by quantifying the formation of phosphorylated products. Advanced formats in this category include:

• Luminescence-based assays: Detect the kinase reaction by measuring ATP consumption or ADP (adenosine diphosphate) formation (e.g., ADP-Glo®, Kinase-Glo®).
• Fluorescence-based assays: Use fluorescently labeled substrates or detection reagents to monitor kinase reactions, increasing sensitivity and enabling miniaturization for large-scale screening (e.g., Time-Resolved Förster Resonance Energy Transfer (TR-FRET), fluorescence intensity)
• Mobility shift assays: Use capillary electrophoresis or similar technologies to separate phosphorylated from non-phosphorylated substrates based on charge or size, providing direct, quantitative readouts of kinase activity without radioactivity.

2. Binding assays assess the binding affinity of small molecules (like inhibitors) to the kinase, often to the ATP-binding site. They include:

• ELISA-based formats: Immunoassay that quantifies phosphorylated substrates or kinase-related antigens through specific antibody binding.
• Thermo kinase assay: Uses thermal shift to assess binding events or conformational changes in the kinase protein.
• Fluorescence Polarization (FP): Measures changes in rotational mobility of fluorescent ligands upon binding to kinases or antibodies.
• TR-FRET/HTRF (Homogeneous Time-Resolved Fluorescence): Detect kinase-ligand interactions with low background interference.
• NanoBRET® and KinomeScan™: Provide real-time or broad kinase panel binding profiles, supporting selectivity and off-target analysis. 

Selection depends on the desired sensitivity, throughput, and assay environment. For example, when working in low-ATP conditions or requiring non-radioactive methods, the in vitro kinase assay non-radioactive protocol can be advantageous.

Enhancing Assay Sensitivity with Fluorescent Ligands

The use of fluorescent ligands has significantly enhanced assay sensitivity and specificity. By incorporating fluorophores into substrates or ATP analogs, researchers can directly monitor binding events, phosphorylation status, or enzymatic turnover in real time.

Advanced approaches like FRET-based kinase assays yield sensitivity greater than traditional radioisotope-based assays, with reduced false positives and simplified protocols. Other methods, such as fluorescence-quenching and fluorescence intensity assays, allow for direct measurement of kinase-ligand interactions and kinase activity without laborious washing steps. These are particularly useful for screening large compound libraries and identifying selective kinase inhibitors.

Incorporating fluorescent ligands into kinase assay protocols enhances sensitivity, allows for lower enzyme and substrate concentrations, enables real-time monitoring, supports simultaneous analysis of multiple targets, and is suitable for miniaturized and automated formats.

Figure 2. Example of fluorescence-guided diagnosis and therapy using fluorescent kinase inhibitors. Source: Ganai AM, Vrettos EI, Kyrkou SG, Zoi V, Khan Pathan T, Karpoormath R, Bouziotis P, Alexiou GA, Kastis GA, Protonotarios NE, Tzakos AG. Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy. Cancers (Basel). 2024 Oct 30;16(21):3667. 

Troubleshooting and Optimizing Kinase Assay Performance

Optimizing a biochemical assay procedure for kinases involves several key factors to ensure reliable and reproducible results:

• Assay and readout selection: Consider sensitivity, throughput, and cost.
• Enzyme and substrate concentrations: Avoid substrate depletion or product inhibition.
• Reaction conditions: Maintain optimal pH and temperature.
• Dimethyl sulfoxide (DMSO) concentration: Determine the solvent level that minimizes impact on kinase activity and signal.

Common pitfalls in kinase biochemical assays

Despite technological advances, several challenges can compromise biochemical testing methods:

• Compound interference: Certain compounds may fluoresce or quench signals, resulting in false positives or negatives.
• Non-specific inhibition: Certain molecules may indirectly inhibit kinases, such as by chelating cofactors.
• Reagent purity: Impurities in ATP, substrates, or buffers can affect reaction kinetics.
• Protein aggregation: Aggregated kinases may display reduced or altered activity.
• Assay format mismatch: Not all formats suit every kinase or inhibitor; cross-validation with multiple methods is recommended.

Anticipating and addressing these pitfalls is essential to ensure reliable data and avoid costly setbacks in later stages of drug development.

As kinase targeting expands across therapeutic areas, the need for reliable, scalable, and sensitive biochemical assays grows. Innovations such as ADP-Glo, fluorescent ligands, and refined kinase assay kits are transforming how researchers approach kinase assay principle design and implementation.

At Celtarys, we develop advanced fluorescent tools to help researchers uncover precise biochemical interactions and accelerate drug discovery workflows. If you’re exploring how to improve your biochemical kinase assay, integrate fluorescent ligands, or troubleshoot a kinase assay protocol, get in touch with our team. 

We’d be glad to support your next breakthrough!

References

Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5. Erratum in: Nat Rev Drug Discov. 2021 Oct;20(10):798. doi: 10.1038/s41573-021-00303-4

Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther. 2021 Dec 20;6(1):423. doi: 10.1038/s41392-021-00826-7

Jia Y, Gu XJ, Brinker A, Warmuth M. Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Discov. 2008 Aug;3(8):959-78. doi: 10.1517/17460441.3.8.959

Schwalm MP, Knapp S. Single-plate kinome screening in live-cells to enable highly cost-efficient kinase inhibitor profiling. SLAS Discov. 2025 Mar;31:100214. doi: 10.1016/j.slasd.2025.100214

Cho H, Lee CS, Kim TH. Label-Free Assay of Protein Kinase A Activity and Inhibition Using a Peptide-Based Electrochemical Sensor. Biomedicines. 2021 Apr 13;9(4):423. doi: 10.3390/biomedicines9040423

Jacobson KA, Pradhan B, Wen Z, Pramanik A. New paradigms in purinergic receptor ligand discovery. Neuropharmacology. 2023 Jun 1;230:109503. doi: 10.1016/j.neuropharm.2023.109503. Epub 2023 Mar 13. Erratum in: Neuropharmacology. 2023 Dec 15;241:109731. doi: 10.1016/j.neuropharm.2023.109731 

Ganai AM, Vrettos EI, Kyrkou SG, Zoi V, Khan Pathan T, Karpoormath R, Bouziotis P, Alexiou GA, Kastis GA, Protonotarios NE, Tzakos AG. Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy. Cancers (Basel). 2024 Oct 30;16(21):3667. doi: 10.3390/cancers16213667